Efficacy of the Enquiring About Tolerance (EAT) study among infants at high risk of developing food allergy
Michael R. Perkin; Kirsty Logan; Henry T. Bahnson; Tom Marrs; Suzana Radulović; Joanna Craven; Carsten Flohr; E. N. Clare Mills · 2019 · Journal of Allergy and Clinical Immunology
WASTE classifies this as Negative / Null Result Report · AI classification, approximate
The study found no significant effect — useful as a negative control or null benchmark for your own design.
The finding, in one line
“The intervention effect did not reach statistical significance in the intention-to-treat analysis of the primary outcome.”
Abstract
BACKGROUND: The Enquiring About Tolerance (EAT) study was a randomized trial of the early introduction of allergenic solids into the infant diet from 3 months of age. The intervention effect did not reach statistical significance in the intention-to-treat analysis of the primary outcome. OBJECTIVE: We sought to determine whether infants at high risk of developing a food allergy benefited from early introduction. METHODS: A secondary intention-to-treat analysis was performed of 3 groups: nonwhite infants; infants with visible eczema at enrollment, with severity determined by SCORAD; and infants
Abstract by Michael R. Perkin; Kirsty Logan; Henry T. Bahnson; Tom Marrs; Suzana Radulović; Joanna Craven; Carsten Flohr; E. N. Clare Mills, Journal of Allergy and Clinical Immunology (2019) — licensed CC BY 4.0.
About to run something similar?
Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.
Related failures
A Randomized Trial of Intraarterial Treatment for Acute Ischemic Stroke
Negative / Null Result ReportDuodenal Infusion of Donor Feces for Recurrent Clostridium difficile
Negative / Null Result ReportStenting versus Endarterectomy for Treatment of Carotid-Artery Stenosis
Negative / Null Result ReportEffects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
Replication FailureA Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Negative / Null Result ReportSpironolactone for Heart Failure with Preserved Ejection Fraction
WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.
Metadata source: OpenAlex · DOI 10.1016/j.jaci.2019.06.045
